← Back

Wire · operational-macro

FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke

Published

10 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ajmc.com →

◆ Verified

Fusion42 · 10 November 2026 · Fusion42 review

The FDA approved asundexian, the first oral factor XIa inhibitor, to reduce the risk of recurrent stroke in adults after mild-to-moderate noncardioembolic ischemic stroke or high-risk transient ischemic attack. This approval follows the phase 3 OCEANIC-STROKE trial demonstrating a 26% reduction in recurrent ischemic stroke risk without increased major bleeding.

This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

Stroke treatment founders can now focus on integrating factor XIa inhibition asundexian into post-stroke care, carving out new opportunities in stroke recurrence reduction. You must revise your pipeline to include this oral inhibitor as a competitive must-have or risk losing share to Bayer's newly approved drug.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalstroke-preventionpharmaclinical-trialanticoagulant